Acute Ischemic Stroke Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Genentech, NoNO, Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Ischemic Stroke pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acute Ischemic Stroke Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market.

Some of the key takeaways from the Acute Ischemic Stroke Pipeline Report: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Acute Ischemic Stroke treatment therapies with a considerable amount of success over the years.
• Acute Ischemic Stroke companies working in the treatment market are Saillant Therapeutics, Avilex Pharma, NeuroTrauma Science, Prolong Pharmaceutical, Ever Supreme BioTechnology, NC Medical Research, Inc., Lumosa Therapeutics Co., Ltd., Revalesio Corporation, Biogen, ZZ Biotech, NoNO Inc., GNT Pharma, and others, are developing therapies for the Acute Ischemic Stroke treatment
• Emerging Acute Ischemic Stroke therapies in the different phases of clinical trials are- ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS007), 3K3A-APC, Nerinetide, Nelonemdaz, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.
• In June 2023, Twist Bioscience Corporation has published preclinical data demonstrating the potential of their highly potent and optimized GLP-1R antagonist antibody, TB-222-023, as a treatment for congenital hyperinsulinism (CHI).
• In May 2022, Boehringer Ingelheim has commenced a study named "DIRECT Thrombectomy vs. Intravenous TNK plus Thrombectomy," focusing on the comparison between Endovascular Treatment alone and Endovascular Treatment preceded by systemic thrombolysis with Tenecteplase in cases of Acute Ischemic Stroke caused by significant intracranial vessel occlusion.
• In February 2022, Lumosa Therapeutics Co., Ltd. has launched a Phase II clinical trial comprising two parts, designed as a double-blind, randomized, and placebo-controlled study. The trial aims to assess the safety and effectiveness of the LT3001 drug product in individuals experiencing Acute Ischemic Stroke (AIS) and undergoing endovascular thrombectomy (EVT). Participants in this study are expected to receive the standard of care (SoC) for AIS treatments as deemed suitable.
• In February 2022, Acticor Biotech released encouraging results from its Phase Ib/IIa ACTIMIS clinical trial evaluating glenzocimab as an additional therapy alongside standard care for patients with acute ischemic stroke (AIS). The study successfully achieved its primary objective, demonstrating the favorable safety profile of glenzocimab.
• In February 2022, Bayer revealed that the U.S. Food and Drug Administration (FDA) has awarded Fast Track Designation to its investigative medication asundexian (BAY2433334) for potential use as a treatment in secondary prevention for patients who have experienced non-cardioembolic ischemic stroke.

Acute Ischemic Stroke Overview
Acute ischemic stroke (AIS) occurs when blood flow to a part of the brain is abruptly interrupted or significantly reduced, leading to a lack of oxygen and nutrients necessary for brain cells to function. This blockage is usually caused by a blood clot that has formed in an artery supplying the brain or has traveled from another part of the body.

Get a Free Sample PDF Report to know more about Acute Ischemic Stroke Pipeline Therapeutic Assessment:
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:
• ST-01: Saillant Therapeutics
• AVLX 144: Avilex Pharma
• NTS-104: NeuroTrauma Science
• PP-007: Prolong Pharmaceutical
• UMSC01: Ever Supreme BioTechnology
• NCS-01: NC Medical Research, Inc.
• LT3001: Lumosa Therapeutics Co., Ltd.
• RNS60: Revalesio Corporation
• BIIB131 (TMS007): Biogen
• 3K3A-APC: ZZ Biotech
• Nerinetide: NoNO Inc.
• Nelonemdaz: GNT Pharma

Acute Ischemic Stroke Route of Administration
Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Ischemic Stroke Molecule Type
Acute Ischemic Stroke Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Acute Ischemic Stroke Pipeline Therapeutics Assessment
• Acute Ischemic Stroke Assessment by Product Type
• Acute Ischemic Stroke By Stage and Product Type
• Acute Ischemic Stroke Assessment by Route of Administration
• Acute Ischemic Stroke By Stage and Route of Administration
• Acute Ischemic Stroke Assessment by Molecule Type
• Acute Ischemic Stroke by Stage and Molecule Type
DelveInsight's Acute Ischemic Stroke Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Ischemic Stroke product details are provided in the report. Download the Acute Ischemic Stroke pipeline report to learn more about the emerging Acute Ischemic Stroke therapies
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Acute Ischemic Stroke Therapeutics Market include:
Key companies developing therapies for Acute Ischemic Stroke are - Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

Acute Ischemic Stroke Pipeline Analysis:
The Acute Ischemic Stroke pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Ischemic Stroke with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Ischemic Stroke Treatment.
• Acute Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Ischemic Stroke market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Ischemic Stroke drugs and therapies
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Ischemic Stroke Pipeline Market Drivers
• Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Acute Ischemic Stroke Market.

Acute Ischemic Stroke Pipeline Market Barriers
• However, challenges associated with the clinical research, challenges associated with the diagnosis of Acute Ischemic Stroke and other factors are creating obstacles in the Acute Ischemic Stroke Market growth.

Scope of Acute Ischemic Stroke Pipeline Drug Insight
• Coverage: Global
• Key Acute Ischemic Stroke Companies: Saillant Therapeutics, Avilex Pharma, NeuroTrauma Science, Prolong Pharmaceutical, Ever Supreme BioTechnology, NC Medical Research, Inc., Lumosa Therapeutics Co., Ltd., Revalesio Corporation, Biogen, ZZ Biotech, NoNO Inc., GNT Pharma, and others
• Key Acute Ischemic Stroke Therapies: ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS007), 3K3A-APC, Nerinetide, Nelonemdaz, and others
• Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
• Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers

Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acute Ischemic Stroke Report Introduction
2. Acute Ischemic Stroke Executive Summary
3. Acute Ischemic Stroke Overview
4. Acute Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment
5. Acute Ischemic Stroke Pipeline Therapeutics
6. Acute Ischemic Stroke Late Stage Products (Phase II/III)
7. Acute Ischemic Stroke Mid Stage Products (Phase II)
8. Acute Ischemic Stroke Early Stage Products (Phase I)
9. Acute Ischemic Stroke Preclinical Stage Products
10. Acute Ischemic Stroke Therapeutics Assessment
11. Acute Ischemic Stroke Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acute Ischemic Stroke Key Companies
14. Acute Ischemic Stroke Key Products
15. Acute Ischemic Stroke Unmet Needs
16 . Acute Ischemic Stroke Market Drivers and Barriers
17. Acute Ischemic Stroke Future Perspectives and Conclusion
18. Acute Ischemic Stroke Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Acute Ischemic Stroke Market https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Ischemic Stroke Epidemiology https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Ischemic Stroke Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Graft Versus Host Disease Market http://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft-versus-host Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Implantable Cardioverter Defibrillators Market http://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
DelveInsight's 'Implantable Cardioverter Defibrillators (ICDs) - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Implantable Cardioverter Defibrillators (ICDs) and the historical and forecasted Implantable Cardioverter Defibrillators (ICDs) market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.